Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy Subjects

Phase 1 Completed 52 enrolled ViiV Healthcare GlaxoSmithKline · collab

Non-randomizedSingle-groupOpen-labelBasic science

Summary

A single oral dose study in subjects with hepatic impairment and healthy control subjects. Subjects will stay at the clinical facility where interval blood samplings will be obtained and examined for drug effect.

Timeline

Start: 2015-01-29
Primary completion: 2015-10-03
Completion: 2015-10-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Fostemsavir	Other / unclassified	—	Oral

Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy Subjects

Summary

Timeline

Drugs

Indications